Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma.

Lindén, A; Hansson, Lennart; Andersson, A; Palmqvist, M; Arvidsson, P; Löfdahl, Claes-Göran; Larsson, P; Lötvall, J

Published in:
Thorax

DOI:
10.1136/thorax.58.3.217

2003

Link to publication

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Bronchodilation by an inhaled VPAC2 receptor agonist in patients with stable asthma

A Lindén, L Hansson, A Andersson, M Palmqvist, P Arvidsson, C-G Löfdahl, P Larsson and J Lötvall

doi:10.1136/thorax.58.3.217

Updated information and services can be found at:
http://thorax.bmjjournals.com/cgi/content/full/58/3/217

Rapid responses
These include:
You can respond to this article at:
http://thorax.bmjjournals.com/cgi/eletter-submit/58/3/217

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections
• Asthma (1043 articles)

Notes

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to Thorax go to:
http://www.bmjjournals.com/subscriptions/
Bronchodilation by an inhaled VPAC₂ receptor agonist in patients with stable asthma

A Lindén, L Hansson, A Andersson, M Palmqvist, P Arvidsson, C-G Löfdahl, P Larsson, J Lötvall

Background: The synthetic vasoactive intestinal peptide (VIP) analogue Ro 25-1553 is a selective VIP-PACAP type 2 (VPAC₂) receptor agonist that causes a bronchodilatory effect in guinea pigs in vivo. The effect of Ro 25-1553 given by inhalation to patients with asthma was studied and compared with that of a long acting β₂ adrenoceptor agonist.

Methods: Twenty four patients with moderate stable asthma participated in a double blind, randomised, placebo controlled, crossover study. The primary variable was bronchodilatory effect (increase in forced expiratory volume in 1 second, FEV₁) after inhalation of Ro 25-1553 (100 µg or 600 µg) and formoterol (4.5 µg), respectively. Putative side effects were characterised by monitoring sitting blood pressure, serum potassium, electrocardiography and echocardiography.

Results: Inhalation of 600 µg Ro 25-1553 caused a rapid bronchodilatory effect (geometric mean increase in FEV₁, compared with placebo) within 3 minutes of 6% (95% CI 4 to 9), as did inhalation of formoterol (8% (95% CI 5 to 10)). The corresponding maximum bronchodilatory effect during 24 hours was similar for 600 µg Ro 25-1553 (7% (95% CI 4 to 10)) and the reference bronchodilator formoterol (10% (95% CI 7 to 12)). However, for both doses of Ro 25-1553 the bronchodilatory effect was attenuated 5 hours after inhalation whereas formoterol still had a bronchodilatory effect 12 hours after inhalation. Neither Ro 25-1553 nor formoterol produced any clinically relevant side effects. No drug related difference in adverse events was observed.

Conclusion: Inhalation of a synthetic selective VPAC₂ receptor agonist constitutes a promising approach for bronchodilation in patients with asthma.

METHODS
Patients with asthma

Patients were recruited from patient files within the three centres involved in the study. The inclusion criteria were male sex, outpatient care, age 18–60 years of age, and a history of stable asthma as defined by the American Thoracic Society.

Patients had to have a baseline FEV₁ of >60% predicted and >100predicted, and FEV₁ reversibility of ≥15%. Only patients who, apart from their asthma, were judged healthy by physical examination, vital signs, electrocardiography and clinical laboratory tests were included. All included patients were able to use the inhalation devices. The exclusion criteria for the study were oral glucocorticoid treatment, β₂ adrenoceptor blocker treatment, or a respiratory tract infection during the 4 weeks before the study, scheduled inpatient surgery during the study, hypersensitivity to β₂ adrenoceptor agonists or lactose, tobacco smoking during the 6 months before the study, abnormal echocardiogram, blood donation during the 3 months before the study, known alcohol or other drug abuse, previous randomisation in the study, or participation in another clinical study within 4 weeks of the current one. Inhaled long acting β₂ adrenoceptor agonists were not allowed during the study and had to be withdrawn at least 72 hours before visit 1.
The study was approved by the independent ethics committee at the Medical Faculties of Göteborg, Lund and Uppsala University, respectively, and was conducted in accordance with the Helsinki Declaration. All patients gave oral and written informed consent before participating in the study. Good clinical practice procedures were applied and the study was monitored by the sponsor (AstraZeneca R&D, Lund, Sweden).

Protocol
This was a placebo controlled study with a double blind, crossover, double dummy design, comprising a total of six study visits. Visit 1 constituted a screening visit for informed consent and enrolment, as well as standard physical examination, lung function and reversibility testing. All patients underwent supervised practice with the inhalation devices (specified below) at visit 1. Provided that the dose was kept constant for at least 4 weeks before the study, inhaled and nasal glucocorticoids, disodium cromoglicate and antihistamines were allowed during the study. Inhalation of short acting β₂ adrenergceptor agonists and/or ipratropium bromide was allowed during the study, provided that dosing did not occur within 6 and 8 hours, respectively, before the administration of randomised treatment. Visit 2 constituted the first visit for randomised treatment and took place 1–14 days after visit 1. Visit 3–5 were also treatment visits and took place 3–14 days after the preceding visit. After receiving the randomised treatment in the morning at visits 2–5, the patient remained at the clinic for 12 hours and returned to the clinic for a 24 hour assessment during the following morning. Visit 6 was a follow up visit which took place 3–5 days later and included a physical examination.

Lung function
Forced expiratory volume in 1 second (FEV₁) was the primary variable of the study and all other variables were regarded as secondary. FEV₁ was assessed using a standard spirometer (Vitalograph Alpha, Vitalograph Ltd, Buckingham, UK) at visits 1–5. The reversibility test at visit 1 was conducted before and 15 minutes after one inhalation of terbutaline 0.5 mg (Bricanyl Turbuhaler, Astra Pharmaceutical Production, Sweden). For each FEV₁, recording during visits 2–5, the best of three FEV₁, measurements was used for evaluation. Throughout the study the FEV₁ had to be within ±12% of the baseline FEV₁, at visit 1. Patients were rescheduled up to two times if this criterion was not fulfilled. At visits 2–5 FEV₁ was assessed 15 minutes before and 3, 15, 30, 45, 60, 90 minutes and hourly for up to 12 hours after treatment. A final FEV₁ assessment was performed 24 hours after treatment.

Vital signs
The pulse rate, systolic and diastolic blood pressure assessments were performed at the same time points as FEV₁ (see above). In addition, sitting blood pressure was assessed before and 30, 60 and 90 minutes and hourly for up to 12 hours after treatment.

Electrocardiography (ECG)
The following ECG parameters were collected at visits 1 and 6 as well as before and 60 minutes, 12 and 24 hours after each randomised treatment at visits 2–5: conduction, extra systoles, heart rate, QRS duration, QT interval, PR interval, sinus rhythm, and ST-T changes. These parameters, plus QTc and QTc dispersion, were finally evaluated after the completion of the study.

Echocardiography
Two dimensional echocardiography was carried out in accordance with standard clinical procedures by a skilled investigator for the evaluation of pericardial fluid (normal or abnormal) at visits 1 and 6 as well as before and 24 hours after each randomised treatment at visits 2–5. This was done because a preliminary safety study on primates (Cynomolagus), conducted by other investigators, indicated an increased amount of pericardial fluid in some subjects after inhalation of Ro 25-1553 (unpublished data).

Clinical laboratory tests
Blood samples for control of serum potassium levels were collected at visits 1 and 6, as well as before and 12 hours after each randomised treatment at visits 2–5. Blood haemoglobin, haematocrit, red blood cells, platelets, white blood cells, differential blood cell count, serum levels of calcium, ASAT, ALAT, ALP GT, bilirubin (total), albumin, sodium, creatinine, urea, glucose, chloride, and C reactive protein, and urinary protein, haemoglobin, erythrocytes, and glucose were also measured at these time points. All these samples were analysed using methods of standard clinical practice (Quintiles AB, Uppsala).

Adverse events
The adverse event profile was evaluated by means of open standardised questions at visits 2–6 and, when needed, by additional physical examination.

Study drugs
The study drugs were delivered at visits 2–5. The nebuliser solution of the synthetic VIP analogue Ro 25-1553 (trifluorometacarboxylic acid) was manufactured by Pharmaceutical and Analytical R&D, AstraZeneca R&D, Lund, Sweden and was delivered for inhalation as an aerosol (100 µg or 600 µg delivered dose free peptide) using a nebuliser (HaloLite, Medic-Aid Ltd, UK). The corresponding placebo aerosol (2 ml of 9 mg/ml saline) was delivered using exactly the same conditions. The reference bronchodilator formoterol fumarate dihydrate was manufactured by Astra Pharmaceutical Production, Sweden and was delivered as inhalation powder (4.5 µg delivered dose) using a commercially available inhaler (Oxis Turbuhaler). The corresponding placebo powder (lactose) was delivered using exactly the same conditions.

Statistical analysis
The primary variable of this study was maximum change in FEV₁ after each treatment. In addition, FEV₁ at 3 minutes and 12 hours after treatment was analysed. The effect of each treatment on FEV₁, was compared using a multiplicative (log transformation of the dependent variable and covariate) analysis of variance model with patient, period, and treatment as fixed factors and the pretreatment FEV₁ as a covariate. From this model, geometric mean treatment differences and corresponding 95% confidence intervals (CI) were calculated. A significance level of 5% was used—that is, differences were considered statistically significant when the 95% CI did not include a 0% increase.

The sample size was based on previous single dose studies with β₂ agonists where the within patient coefficient of variation in 12 hour mean FEV₁ had usually been around 6%. Assuming a similar variability in this study, 24 completed patients would give 80% power to detect a true increase of 5%. This assumed a significance level of 5% and a two sided alternative hypothesis.

RESULTS
Patients
Twenty four men (22 white and two of mixed race) with asthma were initially included in the study. However, one patient discontinued the study at day 10 because of exacerbation of asthma during the washout period after receiving only placebo (randomised treatment) and was not included in the analyses. Another patient received the incorrect treatment by mistake at two visits. Data from these two visits were excluded from analyses. The mean (SD) characteristics of the 23
patients included in the analyses at visit 1 were: FEV1, 3.38 (0.47) l/s corresponding to 78 (7)% of predicted; reversibility 18.7 (3.9)% of FEV1; age 32 (9) years; weight 83 (11) kg; height 182 (8) cm; body mass index 25.1 (3.2) kg/m²; duration of asthma 18.8 (12.0) years. Fourteen of the 23 patients were receiving regular treatment with inhaled glucocorticoids.

Lung function
The mean (SD) baseline FEV1 was 3.40 (0.56) l/s for 100 µg Ro 25-1553, 3.39 (0.51) l/s for 600 µg Ro 25-1553, 3.40 (0.55) l/s for formoterol (4.5 µg), and 3.37 (0.47) l/s for placebo; there were therefore no substantial differences in this parameter before each treatment.

During the 24 hours of lung function monitoring after treatment, the geometric mean maximum increase in FEV1 was 16.2% for 100 µg Ro 25-1553, 18.2% for 600 µg Ro 25-1553, 21.5% for formoterol (4.5 µg), and 10.5% for placebo (as a percentage of baseline before treatment, n=22–23; see fig 1 for maximum CV). Compared with placebo, these differences were statistically significant (geometric mean (95% CI) difference: 5.1% (95% CI 2.8 to 7.6) for 100 µg Ro 25-1553, 7.0% (95% CI 4.5 to 9.5) for 600 µg Ro 25-1553, and 10.0% (95% CI 7.4 to 12.5) for formoterol 4.5 µg). There was no statistically significant difference between 600 µg and 100 µg Ro 25-1553 (geometric mean difference 1.7% (95% CI –0.6 to 4.1)). Formoterol 4.5 µg, however, produced a statistically significantly greater increase than 600 µg Ro 25-1553 (geometric mean difference 2.8% (95% CI 0.4 to 5.3)).

The time course of change in FEV1 during the first 6 hours after each treatment is shown in fig 1. Three minutes after inhalation Ro 25-1553 (100 µg and 600 µg) as well as formoterol (4.5 µg) had increased FEV1, more than placebo. At this time point the geometric mean difference (as a percentage of baseline before treatment) in FEV1, was 4.4% (95% CI 1.9 to 7.0) for 100 µg Ro 25-1553, 6.5% (95% CI 3.8 to 9.2) for 600 µg Ro 25-1553, and 7.8% (95% CI 5.1 to 10.5) for formoterol (4.5 µg) compared with placebo. Five hours after treatment the increasing effect on FEV1, of each dose of Ro 25-1553 was attenuated compared with placebo (fig 1). In contrast, the increasing effect of formoterol on FEV1, remained at 12 hours after treatment (9.7% vs 0.3% for placebo); this difference was statistically significant (geometric mean difference 9.4% (95% CI 4.6 to 14.3)). Neither dose of Ro 25-1553 produced any increasing effect on FEV1, at 12 hours after treatment (100 µg 2.8%; 600 µg -2.5%). Neither treatment produced any increasing effect on FEV1, at 24 hours after treatment (100 µg Ro 25-1553 1.1%; 600 µg Ro 25-1553 –4.1%; 4.5 µg formoterol 5.1%) compared with placebo (2.3%).

Vital signs
Overall, the maximum effect on systolic and diastolic blood pressure was small for all treatments (table 1). Similarly, the effect on pulse rate and sitting blood pressure of each respective treatment was small (data not shown).

Electrocardiography
The maximum effect of each treatment on heart rate and QTc was modest (table 1). Similarly, we were unable to detect any pronounced effect on either conduction, QRS duration, QT interval, PR interval, sinus rhythm, or ST-T changes (data not shown).

Echocardiography
The amount of pericardial fluid was within normal limits for all subjects before and 24 hours after each inhaled treatment (data not shown).

Clinical laboratory tests
The maximum effect of each treatment on serum potassium levels was small (table 1). Only very small changes or no change was seen in the other clinical laboratory tests during each treatment (data not shown).

Adverse events
There was no treatment related difference in reported adverse events (data not shown). No severe adverse events were reported throughout the course of the study.

Table 1 Mean (SD) changes in systolic blood pressure, diastolic blood pressure, heart rate, QTc, and serum potassium levels 12 hours after inhalation of placebo, 100 µg Ro 25-1553 (Ro 100), 600 µg Ro 25-1553 (Ro 600), or 4.5 µg formoterol (Fo 4.5); n=22–23

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Ro 100</th>
<th>Ro 600</th>
<th>Fo 4.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic blood pressure (mm Hg)</td>
<td>16.2 (11.0)</td>
<td>15.9 (9.4)</td>
<td>14.4 (8.8)</td>
<td>18.7 (12.1)</td>
</tr>
<tr>
<td>Diastolic blood pressure (mm Hg)</td>
<td>-7.5 (4.6)</td>
<td>-7.3 (6.2)</td>
<td>-11.6 (4.9)</td>
<td>-7.1 (5.2)</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>-0.4 (6.5)</td>
<td>0.2 (6.6)</td>
<td>2.9 (7.2)</td>
<td>0.9 (6.0)</td>
</tr>
<tr>
<td>QTc (ms)</td>
<td>2.7 (18.1)</td>
<td>5.2 (21.2)</td>
<td>5.3 (14.7)</td>
<td>5.8 (21.7)</td>
</tr>
<tr>
<td>Serum potassium (mmol/l)</td>
<td>0.00 (0.33)</td>
<td>0.03 (0.30)</td>
<td>-0.07 (0.34)</td>
<td>-0.01 (0.34)</td>
</tr>
</tbody>
</table>

Values sampled as followed: blood pressure sitting (repeatedly during 24 hours, see Methods), heart rate and QTc (from ECG conducted at 1, 12 and 24 hours), serum potassium (at 12 hours).
DISCUSSION

Using the synthetic VIP analogue Ro 25-1553, this study is the first to show that inhalation of a selective VPAC, receptor agonist, can cause a clinically relevant bronchodilatory effect in patients with moderate stable asthma.

Ro 25-1553 was selected as a potential bronchodilator because of its advantageous combination of an aromatic amino acid sequence in the N-terminal domain, C-terminal helix, and its increased resistance to proteolytic degradation at key amino acid sites. In contrast to original VIP, the Ro 25-1553 molecule with its lactam ring inhibits airway smooth muscle tone not only in naive but also in inflamed airways.

This has previously been shown by its effect on allergen induced smooth muscle tone in sensitised guinea pig airways in vivo, in vitro and in perfused airways. Furthermore, ro 25-1553 exerted anti-inflammatory effects in the airways of patients with asthma is facilitated by the ability of Ro 25-1553 to inhibit airway smooth muscle contraction caused by several pathogenetically relevant stimuli, as has been demonstrated in vitro and in vivo including histamine, leukotriene D4, and carbachol. The fact that the effect of Ro 25-1553 has been virtually unaffected by the β adrenoceptor blocker propranolol in tracheal smooth muscle further underlines the fact that a mechanism is independent of the β adrenoceptor.

When assessing the pharmacotherapeutic potential of Ro 25-1553, it should be emphasised that our study shows a longer duration of action for the reference bronchodilator formoterol than for Ro 25-1553 in the airways of patients with moderate stable asthma. This illustrates the limitation of the guinea pig airway model in which Ro 25-1553 was found to have a relatively long duration of action. Because of its limited duration of action, Ro 25-1553 will probably not be established as a bronchodilator for clinical use in asthma, but the current results should prompt the development of new selective VPAC receptor agonists with an increased duration of action. Such synthetic analogues of VIP may provide a useful complement to the β adrenoceptor agonists in the treatment of asthma.

Our study shows that inhalation of Ro 25-1553 at doses causing a bronchodilatory effect does not lead to any clinically substantial side effects on the cardiovascular system. No pronounced effects were seen on either blood pressure, heart rate, QRS, or pericardial fluid. Furthermore, no significant effects were seen on serum potassium and other clinical laboratory tests. There were no adverse events related to the inhalation of Ro 25-1553.

In addition to its bronchodilatory effect, Ro 25-1553 may exert anti-inflammatory effects. Thus, it has been shown that Ro 25-1553, but not original VIP inhibits allergen induced thromboxane A2 release in sensitised lungs from guinea pigs perfused in vitro as well as allergen induced eosinophil recruitment in sensitised guinea pig airways in vivo. Ro 25-1553 also inhibits endothelin induced release of the proinflammatory cytokines tumour necrosis factor (TNF)-α and interleukin (IL)-12 in human whole blood and in monocytes in vitro, presumably through activation of the VPAC receptor. It remains to be determined whether the bronchodilatory effect of inhaled Ro 25-1553 is paralleled by the anti-inflammatory effects in the airways of patients with asthma.

In conclusion, inhalation of the VPAC, receptor agonist Ro 25-1553 in a single dose causes a rapid bronchodilatory effect in patients with moderate stable asthma without severe cardiovascular side effects. However, because of the limited duration of its bronchodilatory effect, longer acting VPAC, receptor agonists should be developed and the bronchodilatory and anti-inflammatory effects evaluated in patients with asthma.

REFERENCES

LUNG ALERT

Identifying adventure travellers at risk of developing exacerbations of asthma


This Israeli study followed up 180 mild to moderate asthmatics (mean age 23.9 years, 50% female) who were travelling to developing countries for, on average, 4 months. History, examination and spirometric tests were performed before and after exercise.

Asthma attacks during travel were reported by 88 subjects; 32 had their worst ever attack and 11 had life threatening exacerbations. Frequent (>3/week) use of bronchodilators before travel (RR 3.35, p<0.001), emergency department treatment in the previous year, pre-exercise wheezing, and significant wheezing after exercise were all identified as risk factors for worsening of asthma. Intensive trekking was also a risk factor (RR 2.04, p=0.04). It was noted that most subjects failed to foresee the possibility of worsening of their asthma during travel and there was significant underuse of inhaled corticosteroids in all groups.

Further studies are needed to assess the usefulness of optimising asthma control before travel, avoidance of intensive trekking, and the use of crisis management plans to minimise the frequency of asthma attacks in adventure travellers.

A Bhowmik
University College Hospital, London;
A.Bhowmik@qmul.ac.uk